吉西他滨与多西他赛治疗老年晚期非小细胞肺癌的疗效比较  

Comparing the efficacy and the toxic between gemcitabine and docetaxel in the treatment of elder-patients with advanced non-small cell lung cancer

作　　者：安志洁[1] 陈梅慧 郭成业[1] 王大志[1] 张书瑜[1] 李德爱[1] 

机构地区：[1]青岛市市立医院,266071

出　　处：《中国老年保健医学》2015年第6期39-41,共3页Chinese Journal of Geriatric Care

基　　金：青岛市医疗卫生优秀人才培养项目资助(青卫科教字2014[2])

摘　　要：目的观察吉西他滨单药（GEM）方案和多西他赛单药（DOC）方案治疗老年晚期非小细胞肺癌的疗效和毒性反应。方法 50例晚期NSCLC随机分成GEM组和DOC组,入组的每例患者接受至少2个周期以上的GEM或DOC方案的化疗,比较两组不同化疗方案的近期疗效和毒性反应。结果 GEM和DOC两组近期疗效的有效率分别为28.6%和27.5%,两组一年生存率25.2%和24.1%,两者之间无统计学差异。不良反应以粒细胞减少,消化道反应,口腔黏膜炎为主,两者之间对比除Ⅲ~Ⅳ度血小板减少方面,吉西他滨与多西他赛有统计学差异（P〈0.05）外,其余均无统计学差异。结论吉西他滨单药和多西他赛单药化疗方案对晚期NSCLC均有较好的临床疗效,化疗毒副反应虽有所不同,但均可耐受,且老年患者耐受性良好。Objectives To investigate the efficacy and toxicity of gemcitabine and docetaxel on advanced non-small cell lung cancer. Methods 50 elderly patients with advanced non-small cell lung cancerwere divided into the GEM and the DOC group randomly. All the patients had accepted intravenous chemotherapy and preponderated over 2 cycles. A clinical observation on short term effectiveness and adverse effects were carried out in two groups. Results The short term effective rate for advanced non-small cell lung cancer in NP group and TP group was 28. 6% and 27. 5%,respectively. 1-year survival rate was 25. 2% and 24. 1%,respectively. The short term effectiveness in two groups had no statistically significant difference（ P〈0. 05）. The common adverse event were neutrogena omit and catarrh. In Ⅲ ~ Ⅳ platelet-decreasing the two groups were statistical significance（ P〈0. 05）. Other adverse reactions were no-statistical significance between two groups（ P〈0. 05）. Conclusions Gemcitabine and docetaxel are not only effective in the first line treatment of elderly patients with advanced NSCLC but also well toleration raise the patients life of quality.

关 键 词：吉西他滨单药 多西他赛单药 老年晚期 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]